Mengyang Fan

Mengyang Fan

Auto-generated profile, based on publicly available information

Mengyang Fan

Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang 310018, China; Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2020 in Science
Verified
Journal Article
Closed access
PDF file
IKIsaac A. Klein
Isaac A. Klein
ABAnn Boija
Ann Boija
LALena K. Afeyan
Lena K. Afeyan
SHSusana Wilson Hawken
Susana Wilson Hawken
MFMengyang Fan
Mengyang Fan
RYRichard A. Young
Richard A. Young
Drug partitioning in nuclear condensates: There is increasing interest in the function of phase-separated biomolecular condensates in cells because of their distinct properties and expanding roles in important biological processes. Klein et al. considered the fate of small-molecule therapeutics in the context of nuclear condensates (see the Perspective by Viny and Levine). They show that certain antineoplastic drugs have physicochemical properties that cause them to concentrate preferentially in condensates, both in vitro and in cancer cells. This property influences drug activity, and protein mutations that alter condensate formation can lead to drug resistance. Optimizing condensate partitioning may be valuable in developing improved therapeutics. Science , this issue p. 1386 ; see also p. 1314

27 October 2022 in eLife
Verified
Journal Article
Open access
MFMengyang Fan
Mengyang Fan
WLWenchao Lu
Wenchao Lu
JCJianwei Che
Jianwei Che
NKNicholas P Kwiatkowski
Nicholas P Kwiatkowski
YGYang Gao
Yang Gao
NGNathanael S Gray
Nathanael S Gray
The transcription factor TEAD, together with its coactivator YAP/TAZ, is a key transcriptional modulator of the Hippo pathway. Activation of TEAD transcription by YAP has been implicated in a number of malignancies, and this complex represents a promising target for drug discovery. However, both YAP and its extensive binding interfaces to TEAD have been difficult to address using small molecules, mainly due to a lack of druggable pockets. TEAD is post-translationally modified by palmitoylation that targets a conserved cysteine at a central pocket, which provides an opportunity to develop cysteine-directed covalent small molecules for TEAD inhibition. Here, we employed covalent fragment screening approach followed by structure-based design to develop an irreversible TEAD inhibitor MYF-03–69. Using a range of in vitro and cell-based assays we demonstrated that through a covalent binding with TEAD palmitate pocket, MYF-03–69 disrupts YAP-TEAD association, suppresses TEAD transcriptional activity and inhibits cell growth of Hippo signaling defective malignant pleural mesothelioma (MPM). Further, a cell viability screening with a panel of 903 cancer cell lines indicated a high correlation between TEAD-YAP dependency and the sensitivity to MYF-03–69. Transcription profiling identified the upregulation of proapoptotic BMF gene in cancer cells that are sensitive to TEAD inhibition. Further optimization of MYF-03–69 led to an in vivo compatible compound MYF-03–176, which shows strong antitumor efficacy in MPM mouse xenograft model via oral administration. Taken together, we disclosed a story of the development of covalent TEAD inhibitors and its high therapeutic potential for clinic treatment for the cancers that are driven by TEAD-YAP alteration.

22 March 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
WLWenchao Lu
Wenchao Lu
MFMengyang Fan
Mengyang Fan
WJWenzhi Ji
Wenzhi Ji
JTJason Tse
Jason Tse
IYInchul You
Inchul You
NGNathanael S. Gray
Nathanael S. Gray

19 December 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
QWQing Wei
Qing Wei
TYTeng Yang
Teng Yang
JZJiayu Zhu
Jiayu Zhu
ZZZiwen Zhang
Ziwen Zhang
LYLe Yang
Le Yang
XCXiangdong Cheng
Xiangdong Cheng
Purpose: Antibody–drug conjugate (ADC) has had a transformative effect on the treatment of many solid tumors, yet it remains unclear how ADCs exert bystander activity in the tumor microenvironment. Experimental Design: Here, we directly visualized and spatiotemporally quantified the intratumor biodistribution and pharmacokinetics of different ADC components by developing dual-labeled fluorescent probes. Results: Mechanistically, we found that tumor penetration of ADCs is distinctly affected by their ability to breach the binding site barrier (BSB) in perivascular regions of tumor vasculature, and bystander activity of ADC can only partially breach BSB. Furthermore, bystander activity of ADCs can work in synergy with coadministration of their parental antibodies, leading to fully bypassing BSBs and enhancing tumor penetration via a two-step process. Conclusions: These promising preclinical data allowed us to initiate a phase I/II clinical study of coadministration of RC48 and trastuzumab in patients with malignant stomach cancer to further evaluate this treatment strategy in humans.

29 April 2025 in Cancer Research
Verified
Journal Article
Closed access
QWQing Wei
Qing Wei
TYTeng Yang
Teng Yang
ZZZiwen Zhang
Ziwen Zhang
FWFei Wang
Fei Wang
YYyuxuan Yang
yuxuan Yang
XCXiangdong Cheng
Xiangdong Cheng
Trastuzumab deruxtecan (T-DXd) is a transformative HER2-targeting antibody–drug conjugate (ADC) for treating breast cancer. Unfortunately, T-DXd has also been implicated in causing fatal interstitial lung disease (ILD) in multiple clinical trials. A better understanding of the mechanistic basis of these ADC-induced adverse effects could enable development of strategies to prevent or treat T-DXd–related ILD. In this study, we determined that T-DXd–induced ILD represents an off-target adverse event rather than an on-target off-tumor adverse event. To further investigate this phenomenon, an immunocompetent murine model that recapitulates T-DXd–induced ILD events was developed, facilitating in-depth mechanistic studies. Single-cell RNA sequencing in this model implicated alveolar macrophages (AM) as the primary cell type impacted by T-DXd in the lung microenvironment. Intravital microscopy further revealed that AMs resident in perivascular niches directly engulfed blood-circulating T-DXd via Fc–FcγR engagement. This Fc–FcγR interaction with T-DXd triggered a phenotypic shift in AMs from an immunosuppressive to a pro-ILD state, characterized by inflammation and immune activation, mediated through the SPP1 pathways. Finally, mitigating nonspecific T-DXd uptake in the lung by preconditioning perivascular AMs with IgG1 or the parental antibody of T-DXd significantly reduced unintended ADC absorption. These findings elucidate a mechanism by which T-DXd ignites the lung immune microenvironment and underscore the importance of off-target endocytosis by innate immune cells in the development of ADC-related toxicities. Significance: Preconditioning the perivascular niche can prevent lung inflammation induced by antibody-drug conjugate phagocytosis by alveolar macrophages and subsequent SPP1high macrophage differentiation, providing a clinically viable strategy for mitigating interstitial lung disease.

8 April 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PNPengpeng Niu
Pengpeng Niu
YTYanxin Tao
Yanxin Tao
GLGuohao Lin
Guohao Lin
HXHuiqi Xu
Huiqi Xu
QMQingyuan Meng
Qingyuan Meng
MFMengyang Fan
Mengyang Fan